SMIM11B

Across TCGA pan-cancer cohorts, SMIM11B RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated SMIM11B data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher SMIM11B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMIM11B expression acts as an unfavorable survival marker, although some lineages such as CESC and LUSC show a favorable association.

CHOL, READ, and CESC are the cancer types where SMIM11B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Quartile	All	0.113	0.569	<.001	71	view →
READ	OS	Tertile	II,III,IV	0.399	0.809	<.001	67	view →
CESC	DFS	Median	III,IV	0.798	0.501	.006	48	view →
THCA	DFS	Tertile	III,IV	0.765	0.921	.002	24	view →
BLCA	OS	Quartile	All	0.557	0.714	.008	20	view →
COAD	OS	Tertile	III,IV	0.506	0.797	.001	20	view →
LUAD	DFS	Quartile	IV	0.416	0.749	.023	18	view →
LUSC	DFS	Tertile	All	0.585	0.332	.013	16	view →
ESCA	DFS	Tertile	III,IV	0.490	0.263	.020	14	view →
STAD	DFS	Quartile	IV	0.724	0.144	.007	9	view →
BRCA	DFS	Median	IV	0.338	0.639	.022	9	view →
HNSC	OS	Tertile	III,IV	0.352	0.575	.045	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

SMIM11B–CHOL (DFS)

Open the CHOL breakdown →